↓ Skip to main content

Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of…

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, June 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

f1000
1 research highlight platform

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
35 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
Published in
Journal of Experimental & Clinical Cancer Research, June 2013
DOI 10.1186/1756-9966-32-40
Pubmed ID
Authors

Antonio Bianchi, Ferdinando Valentini, Raffaella Iuorio, Maurizio Poggi, Roberto Baldelli, Marina Passeri, Antonella Giampietro, Linda Tartaglione, Sabrina Chiloiro, Marialuisa Appetecchia, Patrizia Gargiulo, Andrea Fabbri, Vincenzo Toscano, Alfredo Pontecorvi, Laura De Marinis

Abstract

Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting pituitary tumors poorly controlled by SSAs alone. No information is available on specific indications for or relative efficacies of PEGV+SSA versus PEGV monotherapy. Aim of our study was to characterize real-life clinical use of PEGV vs. PEGV+SSA for SSA-resistant acromegaly (patient selection, long-term outcomes, adverse event rates, doses required to achieve control).

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 3%
Unknown 34 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 17%
Student > Doctoral Student 6 17%
Researcher 6 17%
Student > Ph. D. Student 3 9%
Student > Master 3 9%
Other 6 17%
Unknown 5 14%
Readers by discipline Count As %
Medicine and Dentistry 13 37%
Agricultural and Biological Sciences 8 23%
Biochemistry, Genetics and Molecular Biology 3 9%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Psychology 2 6%
Other 2 6%
Unknown 5 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2013.
All research outputs
#7,807,576
of 12,443,702 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#280
of 762 outputs
Outputs of similar age
#80,752
of 154,739 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#4
of 9 outputs
Altmetric has tracked 12,443,702 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 762 research outputs from this source. They receive a mean Attention Score of 2.4. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 154,739 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.